During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened ...

New CAR T-cell therapy shows remarkable efficacy in treating relapsed multiple myeloma, achieving high response rates and ...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma patients, including a 100% response in those naïve to B-cell maturation ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

"We want to cure multiple myeloma, one way or another," S. Vincent Rajkumar, MD, chair of the Myeloma Amyloidosis Dysproteinemia Group at Mayo Clinic in Rochester, Minnesota, told MedPage Today ...

The two conditions that AL amyloidosis can overlap with is most commonly MGAS, or a monoclonal gammopathy, and then less commonly, but more severe, would be multiple myeloma.

Ríos-Tamayo R, Krsnik I, Gómez-Bueno M, et al. AL amyloidosis and multiple myeloma: A complex scenario in which cardiac involvement remains the key prognostic factor. Life (Basel) . 2023;13(7):1518.

Multiple myeloma and AL amyloidosis link to plasma cells in the bone marrow. The conditions co-occur in 10–15% of people with MM. Read about the connection.